CAPR CAPRICOR THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1133869 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.5%
TTM net income YoY-81.6%
TTM EPS YoY-38.6%
Revenue 3-yr CAGR349.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-191.1%
Net margin-181.7%
FCF margin-184.8%
EBITDA margin-184.7%
Returns
ROE-48.2%
ROA-35.3%
ROIC (approx.)-47.3%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets14.7%
Debt / equity0.00x
Current ratio7.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $11.13M |
| R&D expense | $29.56M | $28.87M | $27.38M | $23.13M | $20.36M | $22.05M | $18.92M | $14.55M |
| SG&A expense | $15.12M | $14.08M | $9.40M | $6.02M | $5.92M | $5.67M | $6.07M | $4.27M |
| Operating income | -$44.68M | -$42.95M | -$36.77M | -$29.16M | -$26.28M | -$27.72M | -$24.98M | -$7.70M |
| Pretax income | -$42.66M | -$40.73M | -$33.94M | -$30.17M | -$24.57M | -$25.91M | -$24.39M | — |
| Income tax | $0 | $1,600 | $0 | $0 | $0 | $1,600 | $0 | — |
| Net income | -$42.66M | -$40.73M | -$33.94M | -$30.17M | -$24.57M | -$25.91M | -$24.39M | -$7.12M |
| EBITDA | -$43.78M | -$42.38M | -$36.24M | -$28.65M | -$25.79M | -$27.23M | -$24.58M | -$7.32M |
| EPS (basic) | -0.73 | -0.70 | -0.59 | — | -0.54 | -0.57 | -0.53 | — |
| EPS (diluted) | -0.73 | -0.70 | -0.59 | — | -0.54 | -0.57 | -0.53 | — |
| Weighted avg. shares (diluted) | 58.13M | 57.93M | 57.43M | — | 45.72M | 45.71M | 45.64M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $44.28M | $20.94M | $105.42M | $287.85M | $19.51M | $23.24M | $28.79M | $11.29M |
| Short-term investments | $153.30M | $217.00M | $173.19M | $30.28M | $79.06M | $99.56M | $115.98M | $140.23M |
| Current assets | $202.25M | $242.13M | $283.09M | $322.94M | $100.95M | $124.13M | $146.25M | $163.39M |
| PP&E, net | $37.61M | $36.35M | $28.50M | $18.31M | $11.07M | $8.00M | $6.13M | $5.56M |
| Total assets | $330.37M | $368.74M | $326.28M | $355.95M | $126.44M | $133.57M | $153.77M | $170.48M |
| Current liabilities | $29.90M | $32.96M | $33.64M | $35.84M | $28.15M | $28.40M | $22.34M | $21.03M |
| Total liabilities | $120.61M | $122.52M | $47.58M | $50.16M | $42.57M | $28.59M | $26.12M | $25.02M |
| Shareholders' equity | $209.76M | $246.22M | $278.70M | $305.79M | $83.87M | $104.98M | $127.65M | $145.46M |
| Shares outstanding | 58.14M | 58.11M | 57.66M | 57.37M | 45.72M | 45.71M | 45.68M | 45.58M |
| Cash flow statement | ||||||||
| Operating cash flow | -$35.69M | -$31.49M | -$29.25M | -$23.57M | -$19.69M | -$20.12M | -$6.43M | -$14.80M |
| Capital expenditure | $1.81M | $4.06M | $5.12M | $1.66M | $55,843 | $287,738 | $896,007 | $488,798 |
| Free cash flow | -$37.50M | -$35.55M | -$34.38M | -$25.23M | -$19.74M | -$20.41M | -$7.33M | -$15.29M |
| Investing cash flow | $59.90M | -$48.76M | -$154.64M | $43.09M | $15.95M | $14.55M | $23.89M | -$123.38M |
| Financing cash flow | $88,700 | -$4.24M | $1.47M | $248.82M | $6,950 | $19,580 | $50,354 | $81.09M |
| Depreciation & amortization | $900,989 | $561,845 | $534,670 | $502,587 | $494,725 | $486,278 | $405,450 | $375,705 |
| Stock-based compensation | — | — | — | $3.84M | $4.00M | $3.65M | $5.74M | $2.30M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.